ArticleFrontiers in oncology2020
Long Noncoding RNA LOC400043 (LINC02381) Inhibits Gastric Cancer Progression Through Regulating Wnt Signaling Pathway.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A novel model based on ferroptosis-related lncRNAs for predicting prognosis and adjuvant therapy response in colon adenocarcinoma.Discover oncology · 2026Article
- Development and experimental validation of a senescence-related long non-coding RNA signature for prognostic prediction and immune microenvironment characterization in gastric cancer patients.Journal of gastrointestinal oncology · 2024Article
- Identification and verification of inflammatory biomarkers for primary Sjögren's syndrome.Clinical rheumatology · 2024Article
- Construction and validation of stemness-related lncRNA pair signature for predicting prognosis in colorectal cancer.Journal of cancer research and clinical oncology · 2023Article
- A comprehensive insight into the correlation between ncRNAs and the Wnt/β-catenin signalling pathway in gastric cancer pathogenesis.Cell communication and signaling : CCS · 2023Review
- T2DB: A Web Database for Long Non-Coding RNA Genes in Type II Diabetes.Non-coding RNA · 2023Article
- Inhibition of ox-LDL-induced endothelial cell injury by LINC02381 knockdown through the microRNA-491-5p/transcription factor 7 axis.Immunity, inflammation and disease · 2023Article
- LncRNA LINC01537 Promotes Gastric Cancer Metastasis and Tumorigenesis by Stabilizing RIPK4 to Activate NF-κB Signaling.Cancers · 2022Article
- LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.Journal of neuro-oncology · 2022Article
- Epithelial-mesenchymal transition-related long noncoding RNAs in gastric carcinoma.Frontiers in molecular biosciences · 2022Review
- Comprehensive Analysis of RNA-Seq in Endometriosis Reveals Competing Endogenous RNA Network Composed of circRNA, lncRNA and mRNA.Frontiers in genetics · 2022Article
- Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder.Frontiers in pharmacology · 2022Article
- Establishment and Analysis of a Prognostic Model of Autophagy-Related lncRNAs in ESCA.BioMed research international · 2022Article
- N7-methylguanosine-related lncRNAs: Predicting the prognosis and diagnosis of colorectal cancer in the cold and hot tumors.Frontiers in genetics · 2022Article
- Non-coding regions of nuclear-DNA-encoded mitochondrial genes and intergenic sequences are targeted by autoantibodies in breast cancer.Frontiers in genetics · 2022Article
- RHO GTPase-Related Long Noncoding RNAs in Human Cancers.Cancers · 2021Review
- Long noncoding RNA DLGAP1-AS2 facilitates Wnt1 transcription through physically interacting with Six3 and drives the malignancy of gastric cancer.Cell death discovery · 2021Article
- LncRNAs in Cardiomyocyte Maturation: New Window for Cardiac Regenerative Medicine.Non-coding RNA · 2021Review
- Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer.Frontiers in immunology · 2021Article
- ADORA2A-AS1 Restricts Hepatocellular Carcinoma ProgressionFrontiers in oncology · 2021Article
Corrections and comments
- Retraction · 2023-12-05Author Unresponsive · Concerns/Issues about Image · Duplication of/in Image · Investigation by Journal/Publisher · Objections by Author(s) · Original Data and/or Images not Provided and/or not Available · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the common causes of cancer mortality worldwide, with a low survival rate for the affected people. Recent studies have revealed the key role of long non-coding RNAs (lncRNAs) in the development and progression of many cancers, including gastric cancer. Looking for the potential molecular regulators of gastric cancer incidence and progression, LINC02381 was identified as a downregulated lncRNA in gastric cancer tissues by analysis of available microarray and RNA-seq data and RT-qPCR confirmed this differential expression. MiR-21, miR-590, and miR-27a miRNAs were predicted to be sponged by LINC02381, and dual luciferase assay verified LINC02381 as a competitive endogenous RNA (CeRNA), which binds to them. Furthermore, we found that increased expression of LINC02381 attenuates Wnt pathway activity. Also, functional analysis indicates that LINC02381 arrests cell cycle, increases apoptosis and caspase activity, and reduces cell survival and proliferation rate of the human gastric cancer cell lines AGS and MKN45. Moreover, EMT analysis showed that LINC02381 is involved in gastric cancer progression and inhibits metastasis. Overall, this work for the first time introduces LINC02381 as a CeRNA involved in gastric cancer and provides novel insight into the molecular pathogenesis of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.